The Future Of

Neurosurgery

Targeted Delivery of CNS Therapeutics

Most current treatments only target the symptoms of many Neurological diseases but with gene therapies, for the first time, there may be an opportunity to cure many of these conditions. However, many promising treatments are failing clinical trials, not because of the drug itself but because of an inability to deliver the treatment effectively where it needs to go.

Although currently for investigational use only, Neurochase believes it has a solution. Neurochase founder Prof. Steven Gill and medical director Prof. Neil Barua give a quick breakdown of the problems and solutions in the video below.

What do we do?

We are bringing transformative therapies to patients with neurological diseases using state of the art technology. Specialising in creating bespoke therapeutic strategies for the direct delivery of gene and other therapies .

World leading experts

The Neurochase team, which includes world leaders in drug delivery to the CNS, is developing globally scalable delivery solutions for the pharma & biotech industry, enabling them to deliver gene and other therapies safely and effectively.
Neurochase Delivery System

Our Services

Alongside our development of the next generation of CNS drug delivery platforms we provide an array of consultancy and training services on direct delivery to the CNS.
Our pre-clinical support service can help you with protocol development, equipment and devices for optimal drug delivery in studies.

As you move into Clinical trials we can help with protocol development, surgical workflow optimisation and surgeon training and from 2025 access to our revolutionary new CED devices.

News & Articles

Novel Gene Therapy for Motor Neurone Disease (MND) & Parkinson’s (PD)

Innervate Therapeutics is a biotechnology company focused on developing glial cell -derived neurotrophic factor (GDNF) gene therapies to achieve neuro-restoration and neuroprotection in diseases including PD and MND. GDNF, a [...]
Read more

Brain Tumor Therapy – A New Indication For Hamlet Pharma

Original Article Today, Hamlet Pharma signed a joint development agreement with Neurochase Limited, founded by Professor Steven Gill, a world leading expert in the area of neurosurgery, to develop novel [...]
Read more

AviadoBio Announces Formation of Scientific Advisory Board

AviadoBio, a pioneering, pre-clinical stage, gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, announces that it has established a Scientific Advisory Board (SAB) [...]
Read more

CombiGene and Neurochase Preclinical Study

CombiGene’s and Neurochase’s preclinical study provides valuable information for the upcoming long-term studies in toxicology and biodistribution STOCKHOLM — On June 28, 2021, CombiGene (“CombiGene”, “the Company”) announced that the [...]
Read more
© 2024 Neurochase
Privacy Policy